Skip to Main Content

Hours after the biotech company Iovance announced yet another regulatory delay for its investigational cancer treatment, the firm disclosed Wednesday that its CEO had abruptly tendered her resignation, sending its share price plummeting.

Maria Fardis, who has run Iovance since 2016, informed the company on Tuesday that she “will be resigning” from her roles as CEO, president, and board member, the firm said in a two-sentence filing with the Securities and Exchange Commission. Iovance did not specify whether Fardis’s resignation was effective immediately, and the company did not immediately respond to an inquiry. She’s leaving to “pursue other opportunities,” the company said in its filing, and she’ll be replaced on an interim basis by Iovance general counsel Frederick Vogt.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!